RSABE… [Regulatives / Guidelines]

posted by Loky do – Egypt, 2021-02-24 15:30 (78 d 04:45 ago) – Posting: # 22230
Views: 882

Hi Dear Helmut,

Many thanks for your reply :-D:-D

» Which book are you referring to?
»
» For the FDA you can apply RSABE for any PK metric (AUCs, partial AUCs, Cmax, :blahblah:) if its \(\small{s_{\textrm{wR}}\geq 0.294\;(CV_{\textrm{wR}}\geq\approx0.300469\ldots)}\)
» If \(\small{s_{\textrm{wR}}<0.294}\) you have to evaluate the respective PK metric for ABE.

I didn't find this statement in FDA guidance for bioequivalence studies just in progesterone guidance so, is it enough to refer to this guide while submitting the study to regulatory (as the intrasubject variability CV% equal 57%, partially replicate design), or is there another guide would support this way? please advice?

Thanks in advance

Complete thread:

Activity
 Admin contact
21,460 posts in 4,486 threads, 1,511 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Thursday 21:15 CEST (Europe/Vienna)

Nothing in the world is more dangerous
than sincere ignorance
and conscientious stupidity.    Martin Luther King, Jr.

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5